Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
The Russian government will be ready to significantly increase state procurements of drugs against hepatitis C in case of reduction price for them both by global drugmakers and Russian pharmaceutical companies. 31 July 2024
It is predominantly in the USA, Europe and parts of Asia, where advanced new treatments such as cell and gene therapies are being developed, offering hope for better outcomes for patients with diseases like cancer. 31 March 2020
China-based WuXi Biologics, a contract development and manufacturing organization (CDMO), will focus on overseas development as well as efficiency improvement in 2020, said the firm’s chief executive Chris Chen at a press meeting in Shanghai on Friday, reports The Pharma Letter’s correspondent Wang Fangqing. 31 March 2020
As the world watches aghast, the novel coronavirus continues to spread its tentacles around the globe, with cases of COVID-19 rising to nearly 375,000 on Tuesday, an increase of 75,000 from the day before. 25 March 2020
An overview of one of the issues that has been brought into focus by the coronavirus (COVID-19) outbreak by Madhav Durbha, group vice president, industry strategy, LLamasoft, in an Expert View piece. 17 March 2020
Russia may be faced with a significant increase of drug prices in the domestic market by the end of the first quarter of the current year, which will be mainly due to the recent fall of the rouble and a potential shortage of a number of active ingredients the are used by domestic drugmakers and foreign companies operating in the local market. 17 March 2020
US biotech major Gilead Sciences’ recent $4.9 billion buyout of Forty Seven put a spotlight on the latter’s star asset magrolimab, an anti-CD47 monoclonal antibody (MAb), as well as the target CD47, a protein on cancer cells sending out “don’t eat me” signal to avoid phagocytosis by microphages. 13 March 2020
In the USA, approximately 300,000 infants are born with sickle cell disease (SCD) each year.1 In this article, Dr Nicola Davies discusses how SCD is treated and what solutions are on the horizon. 13 March 2020
Leading Russian drugmakers and foreign companies operating in the local market have called on the Russian government to change the existing rules for public procurements of drugs in Russia. 10 March 2020
In response to a sharp price increase in the domestic market caused by the spread of the novel coronavirus (COVID-19), the Russian government and the national Parliament (State Duma) are considering introducing state regulation over prices for drugs and medical devices in the domestic market 10 March 2020
Alessia Deglincerti, Frank Borowsky and Rachel Laing from consulting firm Bionest Partners, explore in an Expert View how the development of spinal muscular atrophy (SMA) therapies could provide a blueprint for genetic diseases. 9 March 2020
Located at the heart of the Cambridge biotech cluster in Massachusetts, Kymera Therapeutics is exploring the notion that targeted protein degradation could provide a way to treat previously untreatable conditions. 9 March 2020
As India looks to avert a potential drug shortage crisis in the wake of escalating COVID-19 cases in the country, a standing committee set up by the Department of Pharmaceuticals and government think-tank Niti Aayog has proposed a $409 million scheme to boost the bulk drug industry. 6 March 2020
As the Indian government scouts for options to deal with any potential active pharmaceutical ingredient (API) scarcity that can arise in the future to counter the new coronavirus (COVID-19), the country's oldest public sector pharmaceutical company, Hindustan Antibiotics Limited (HAL), has submitted a proposal to the government to reduce dependence on China for fermentation-based bulk drugs. 5 March 2020
The production of drugs in Russia may decline significantly this year, due to the almost complete suspension of the supplies of raw materials for their production from China, according to recent statements by representatives of some leading drugmakers in Russia and local analysts, reports The Pharma Letter’s local correspondent. 3 March 2020
Leading Russian doctors along with representatives of local medical communities have called on Russia’s Prime Minister Mikhail Mishustin to ensure the supplies of original drugs to the domestic market, particularly those used for the treatment of some serious diseases, reports The Pharma Letter’s local correspondent. 3 March 2020
Several changes in the marketplace has necessitated that Indian companies proactively shift their business models from supplying commodities to supplying innovations. 26 February 2020
Swiss pharma giant Roche and other global drugmakers are eyeing more active expansion in the former Soviet market within the next several years, according to recent statements by the companies and some regional media reports, reports The Pharma Letter’s Russia correspondent. 25 February 2020
In early December 2019, the first cases of a new coronavirus emerged, a virus that has since come to grip the world’s media and worry regulators in every country. 24 February 2020
Scientists have shown that inflammatory disease in the body is associated with an increased risk of Alzheimer’s, something that is central to the approach taken by US biotech Tetra Therapeutics. 17 February 2020